

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

September 23, 2003

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 19, 2003

**IntraBiotics Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-29993**

(Commission File No.)

**94-3200380**

(IRS Employer Identification No.)

**2483 East Bayshore Road, Suite 100**

**Palo Alto, California 94303**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

---

**TABLE OF CONTENTS**

Item 5. Other Events and Regulation FD Disclosure

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

---

**Table of Contents**

**Item 5. Other Events and Regulation FD Disclosure**

On September 19, 2003, IntraBiotics Pharmaceuticals, Inc. issued a press release entitled, IntraBiotics Reaches Special Protocol Assessment (SPA) Agreement with FDA . This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 7. Financial Statements, *Pro Forma Financial Information* and Exhibits**

*(c) Exhibits.*

99.1 Press Release, dated September 19, 2003, entitled IntraBiotics Reaches Special Protocol Assessment (SPA) Agreement with FDA.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 23, 2003

**INTRABIOTICS PHARMACEUTICALS, INC.**

By: /s/ Eric Bjerkholt

---

Eric H. Bjerkholt  
Sr. Vice President and  
Chief Financial Officer

**Table of Contents**

**INDEX TO EXHIBITS**

99.1 Press Release, dated September 19, 2003, entitled IntraBiotics Reaches Special Protocol Assessment (SPA) Agreement with FDA.